- Home
- OPHC vs MGX Comparison
OPHC vs MGX Comparison
Compare OPHC & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- MGX
- Stock Information
- Founded
- OPHC 2000
- MGX 2018
- Country
- OPHC United States
- MGX United States
- Employees
- OPHC N/A
- MGX N/A
- Industry
- OPHC Major Banks
- MGX
- Sector
- OPHC Finance
- MGX
- Exchange
- OPHC Nasdaq
- MGX NYSE
- Market Cap
- OPHC 51.8M
- MGX 62.1M
- IPO Year
- OPHC N/A
- MGX 2024
- Fundamental
- Price
- OPHC $4.52
- MGX $1.61
- Analyst Decision
- OPHC
- MGX Strong Buy
- Analyst Count
- OPHC 0
- MGX 4
- Target Price
- OPHC N/A
- MGX $13.00
- AVG Volume (30 Days)
- OPHC 8.2K
- MGX 682.1K
- Earning Date
- OPHC 08-05-2025
- MGX 08-13-2025
- Dividend Yield
- OPHC N/A
- MGX N/A
- EPS Growth
- OPHC 30.24
- MGX N/A
- EPS
- OPHC 1.33
- MGX N/A
- Revenue
- OPHC $39,980,000.00
- MGX $45,263,000.00
- Revenue This Year
- OPHC N/A
- MGX N/A
- Revenue Next Year
- OPHC N/A
- MGX $11.75
- P/E Ratio
- OPHC $3.37
- MGX N/A
- Revenue Growth
- OPHC 53.28
- MGX N/A
- 52 Week Low
- OPHC $3.53
- MGX $1.23
- 52 Week High
- OPHC $5.90
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- OPHC 56.95
- MGX 53.96
- Support Level
- OPHC $4.42
- MGX $1.45
- Resistance Level
- OPHC $4.62
- MGX $1.66
- Average True Range (ATR)
- OPHC 0.06
- MGX 0.13
- MACD
- OPHC 0.01
- MGX 0.01
- Stochastic Oscillator
- OPHC 61.54
- MGX 72.13
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.